Quote:

---

So if TAS is knocking out neutrophils while leronlimab depends on those neutrophils to eradicate the tumor, it sounds like the combination of leronlimab with TAS could in some way hamper or mitigate the effects of combining leronlimab to TAS.

What if the reverse is true? What are the chances of leronlimab mitigating the effects of TAS weakening the bone marrow/stem cells and neutrophils?

---

Lowering neutrophil is not great but leronlimab depends on the M1 to M2 macrophage switch. TAS-102 might also lower macrophage counts, but not to the level of neutrophils. The immune system is still intact or otherwise you'd see a larger number of deaths due to opportunistic infections. If macrophage counts are lowered it would not be the best for leronlimab but would be offset by TAS-102's direct killing of tumor cells.

Quote:

---

Why do you think there is less killing of the neutrophils when bevacizumab is added to TAS as you've stated?

---

I haven't stated that.